D. and Mary Margaret Clausen
Distinguished Professor of Medicine , Pathology, Microbiology +
Immunology at the University of California, San Francisco (UCSF ). Olefsky, M., Harry Wm.

nanotechnology plastictalk

"The completion
of the Phase I clinical trial for Sirna-027 in age-related macular
degeneration and the demonstration of systemic efficacy in non-human primates
leading to the selection of a clinical candidate in hepatitis C has
established Sirna as a leading siRNA therapeutics company., has demonstrated that it is safe and well
tolerated with 25 of 26 patients showing visual acuity stabilization and 23%
of those patients experiencing clinically significant improvement in visual
acuity eight weeks after a single injection. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings, including
the Forms 10-K and 10-Q and in other SEC filings.

Contacts:
Rebecca Galler Robison, Senior Director , Corporate Strategy of Sirna
Therapeutics, Inc. In
highlighting the Clinical Breast Care Project , jointly developed
between WRI and its clinical collaborators, Prof.

When:

Wednesday May 25, 2005, 13.com

genomics nanotechnology

Dr.D. His research focuses on
computational models of disease progression stressing risk detection,
disease process modeling and analysis of lifestyle interactions.

cosmology discoveries

Russell
is an expert in lipid metabolism and endocrine disorders

* Xiaodong Wang, Ph. He was also Director of Genomics for Vysis, Inc.

bioethics aeronautics

Dr.D."
"During the past year, Sirna has made important advances in the
development of RNAi-based therapeutics," said Dr. I expect that this
exceptional SAB will make a significant contribution to Sirna's therapeutic
programs and their ultimate success in the clinic.

Presentation by Windber CSO Highlights Application of InforSense KDE to Translational Medicine

cosmology bioethics

W. Gray is an expert in neoplastic
diseases, breast and ovarian cancer in particular

* Stanley M. and Diana V.

inquiries aeronautics

D. Bluestone is an expert in diabetes and immunology

* Beverly Davidson, Ph. Gray
also is Adjunct Professor of Laboratory Medicine at the University of
California, San Francisco (UCSF).D., Eugene McDermott Distinguished Chair in
Molecular Genetics at the University of Texas Southwestern. More information on Sirna Therapeutics is available on the
Company's web site at http://www. For example, most drug candidates do not become
approved drugs., 303-449-6500
Alan Zachary, McKinney Chicago, 312-944-6784 x316

Michael Liebman , Chief Scientific Officer of the Windber
Research Institute (WRI), will describe the ground-breaking
workflow-based informatics platform for translational medicine being
developed in collaboration with InforSense at WRI.50 p. and
Director of Bioinformatics at the Amoco Technology Company.

cosmology convene

"Their deep insight into
the etiology of important human diseases will be instrumental in advancing our
therapeutic programs to the clinic.e. Enabling WRI's multi-disciplinary,
clinical and molecular approach requires both an informatics
infrastructure capable of integrating a wide variety of internal and
external tools, algorithms, data types and data sources and also a
rapid application development platform optimized for such a clinically
driven 'top-down' approach for life science study. - "Redefining Translational
Medicine for Drug Discovery", Prof.

genomics maths

D. Dr.D., George L.com.

Safe Harbor Statement
Statements in this press release which are not strictly historical are
"forward -looking" statements which should be considered as subject to many
risks and uncertainties. He previously was
Global Head of Computational Genomics at Roche Pharmaceuticals and
Director, Bioinformatics and Pharmacogenomics at Wyeth
Pharmaceuticals.

Also provides links to categories for 'chats and forums ' focused in a particular field of science.

transduction metaphysics

, Professor of Medicine and Co-Chair, Division
of Endocrinology + Metabolism at the University of California, San
Diego.m.

able2know inventions

, Professor, Microbiology /Immunology and Medicine at
the University of California, San Francisco and a Howard Hughes Medical
Institute Investigator. Gray, Ph., Associate Laboratory Director for Life and
Environmental Sciences at the Lawrence Berkeley National Laboratory
(LBNL) and the Director of the LBNL Life Sciences Division. Dr. Lemon is an
expert in chronic hepatitis C and innate immunity

* Richard Locksley, M. Dr. Locksley is an
expert in infectious disease and immunology

* Jerrold M. Dr. Sirna undertakes no
obligation to revise or update any forward-looking statements in order to
reflect events or circumstances that may arise after the date of this release. The InforSense
Oracle Edition provides a state of the art solution for enterprise
wide integrative analytics using Oracle's advanced information
management and processing capabilities .inforsense.

monkeys transduction

neuroscience cosmology

Chaired by Dr. Lemon, M. Dr. Yamamoto.

colonization nanotechnology

, Executive
Vice Dean for Research at the University of California, San Francisco School
of Medicine and Chairman of the Sirna SAB are ten world-renowned scientists
who bring expertise in key areas that will be invaluable in transitioning
Sirna's pipeline programs from discovery to the clinic., Director, Institute for Human Infections and
Immunity Professor, Departments of Microbiology + Immunology and
Internal MedicineUniversity of Texas Medical Branch.D. Wells is an expert in molecular recognitions, the
protein design and site-directed design of small molecule ligands

"We are very pleased to bring together these key thought leaders to
establish the Sirna Scientific Advisory Board," stated Barry Polisky , Sirna
Senior Vice President and Chief Scientific Officer. Further, the interest and direct
participation of these world class scientists on our SAB reflects the progress
we're making in the development of RNAi-based therapeutics."

About Sirna Therapeutics
Sirna Therapeutics is a clinical -stage biotechnology company developing
RNAi-based therapies for serious diseases and conditions, including
age-related macular degeneration (AMD), hepatitis B and C, dermatology,
asthma, Huntington 's disease, diabetes and oncology. The development of Sirna-027 and Sirna-034 as well as Sirna's
other programs are still at a relatively early stage and subject to
significant risks and unknowns.

Business Editors/Technology Writers/Health Writers
BIOWIRE2K
Drug Discovery + Technology Leaders Summit
Montreux, Switzerland
InforSense Ltd, the leader
in integrative analytics platforms , invites life science researchers
and media to attend a presentation entitled "Redefining Translational
Medicine for Drug Discovery" at the Drug Discovery + Technology
Leaders Summit to be held in Montreux , Switzerland.
Liebman will describe the effort and the basis for this expanded view.

About InforSense KDE

InforSense KDE, the company's flagship product, consists of a
generic workflow environment for integrative analytics; a workflow
warehouse for capturing, managing and utilizing process knowledge and
Intellectual Property (IP); and a powerful deployment engine to enable
workflows to be rapidly turned into tailored, reusable applications
available through web services or visual applications.

neuroscience plastictalk

has been Chief Scientific Officer at
Windber Research Institute since November 2003 .

About InforSense

InforSense Limited, a privately held corporation, enables
organizations , using a workflow paradigm, to optimize their important
information-driven decision making processes so that information,
expertise and derived knowledge can be delivered effectively and
quickly to decision-makers throughout the organization.

transduction plastictalk

Joining Keith Yamamoto, Ph. Yamamoto, the members of the Sirna Scientific Advisory
Board are:

* Jeffrey A. Russell, Ph. Dr. Sirna has a leading intellectual property
portfolio in RNAi with 50 issued patents and over 250 pending applications
worldwide. Moreover, Sirna's ability to develop products
and operate as a going concern requires significant cash to fund its operating
programs. Michael Liebman, Chief Scientific
Officer of the Windber Research Institute, at the Drug Discovery +
Technology Leaders Summit, Le Montreux Palace , Montreux, Switzerland.

nanotechnology immunology

Ganem is an expert in viral diseases

* Joe W. MacGregor Distinguished Chair in
Biomedical Science at the University of Texas Southwestern Medical
School and a Howard Hughes Medical Institute Investigator. Hind Professorship in
Pharmaceutical Sciences and Professor of Pharmaceutical Chemistry and
Cellular and Molecular Pharmacology at the University of California, San
Francisco. into the clinic. He has
served on the faculty of Mount Sinai School of Medicine in
Pharmacology and Physiology/Biophysics.

plastictalk metaphysics

Bluestone, Ph. Dr.D.D. Sirna Therapeutics has
presented interim Phase 1 clinical trial data for its most advanced compound,
Sirna-027, a chemically optimized siRNA targeting the clinically validated
vascular endothelial growth factor pathway to treat AMD.

Contains newsletters, newsgroups, forums, message boards, and chat rooms which discuss broad science related topics.

inventions monkeys

Wang is
an expert in apoptosis and the RNA interference mechanism

* James A. This approach
maximizes the return on existing Information Technology (IT)
investments and helps organizations meet their evolving business
needs.

anomalies plastictalk

Sirna Therapeutics Announces Its Scientific Advisory Board

Dr. Wells, Ph.

bioethics convene

Olefsky is an expert in type II diabetes and metabolic
diseases

* David W. Sirna-027, which has
been partnered with Allergan , Inc. In addition, Sirna recently
announced that it has selected Sirna-034, a systemically delivered , optimized
siRNA compound, as its candidate for advancement to human clinical testing
against Hepatitis C virus.sirna. This presentation
by Prof. Liebman will
demonstrate how their approach critically requires the need to also
move from "bedside to bench". Prior to this he was
Director , Computational Biology and Biomedical Informatics at the
Abramson Family Cancer Research Institute of the University of
Pennsylvania Cancer Center since September 2000. InforSense customers include leading pharmaceutical and
biotechnology companies, financial services companies, and leading
research institutes.

bioethics transduction

Both requirements
will be met through the collaboration with InforSense and Prof. Liebman Ph.

genomics convene

Davidson is an expert in neurodegenerative diseases and the
therapeutic use of siRNAs

* Donald Ganem, M., Herbert and Marion Sandler Distinguished
Professorship in Asthma Research; Professor of Medicine and
Microbiology/Immunology, at the University of California , San Francisco
and a Howard Hughes Medical Institute Investigator. Dr. Additional risks and uncertainties include Sirna's early stage of
development and short operating history, Sirna's history and expectation of
losses and need to raise capital, the rate at which Sirna uses cash, the
timing of receipt of development milestone payments from collaborating
partners, Sirna's need to obtain clinical validation and regulatory approval
for products, Sirna's need to obtain and protect intellectual property, risk
of third-party patent infringement claims, Sirna's need to attract and retain
qualified personnel, Sirna's need to engage collaborators, availability of
materials for product manufacturing , the highly competitive nature of the
pharmaceutical market, the limited trading volume and history of volatility of
Sirna's common stock, Sirna's concentration of stock ownership, and risks from
relocating Sirna headquarters. For further information on
InforSense products and solutions, visit www.

bioethics maths

Eleven Renowned Researchers to Guide Sirna's Advancing Therapeutic Pipeline

SAN FRANCISCO, Sirna Therapeutics
(Nasdaq: RNAI), a leading RNAi therapeutics company, has announced its
Scientific Advisory Board (SAB). He is
the Director of the UCSF Diabetes Center, the Immune Tolerance Network,
and the Juvenile Diabetes Research Foundation Collaborative Center for
Cellular Therapy., Roy J. Carver Professor in Internal Medicine
and Professor in Neurology, Physiology + Biophysics at the University of
Iowa.D.

About Michael Liebman

Michael N.

beekeeping aeronautics

, A .D.
Traditionally translational medicine has meant the translation of
research at the bench to the bedside, i.